GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, today emphasized the strategic positioning of its oncology asset, Gedeptin® (Ad/PNP), in light of accelerating industry investment in next-generation in vivo cancer therapies. The company believes Gedeptin is uniquely positioned to address the challenge of immunologically 'cold' tumors, which limit the effectiveness of advanced therapeutic modalities.
Recent high-profile transactions and investments across the biopharmaceutical sector underscore a growing focus on therapies designed to simplify delivery, improve scalability, and expand therapeutic reach. However, many tumors remain immunologically 'cold,' hindering even the most advanced treatments. GeoVax asserts that Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT), can positively modify the local tumor environment, a critical determinant of clinical success.
'Gedeptin is designed to directly destroy both proliferating and non-proliferating tumors, while also demonstrating high bystander activity due to the ability of the in situ generated cytotoxic agent to diffuse into neighboring tumor cells,' said David A. Dodd, Chairman and Chief Executive Officer of GeoVax.
Gedeptin is delivered intratumorally and generates purine nucleoside phosphorylase (PNP), which selectively destroys tumor cells. In preclinical models, PNP treatment has shown additive or synergistic effects with checkpoint blockade agents. Studies in metastatic tumor models demonstrated that treating a single lesion can sensitize tumors to checkpoint inhibitors, presumably by destroying tumor tissue, exposing neoantigens, and enhancing immune response at distant untreated lesions. This dual mechanism—localized cytotoxicity combined with immune enhancement—could offer an improved approach to treating solid tumor metastatic disease.
GeoVax has generated preclinical, clinical, and translational data supporting Gedeptin's ability to induce localized tumor cell death while minimizing systemic toxicity and potentially improving response rates when combined with immune checkpoint inhibitors. As checkpoint inhibitors move earlier in treatment paradigms, the need for complementary approaches that enhance response rates is becoming increasingly evident.
The company is advancing Gedeptin in combination with checkpoint inhibition in a planned Phase 2 clinical trial in first-line head and neck cancer therapy, with additional solid tumor indications under evaluation. 'Checkpoint inhibitors have transformed cancer care, but many patients still do not achieve durable responses. We believe Gedeptin is well positioned as a combination-enabling platform designed to enhance therapeutic response across checkpoint inhibitors and other emerging oncology modalities,' said Kelly T. McKee, M.D., Chief Medical Officer of GeoVax.
Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers. GeoVax continues to evaluate strategic partnerships and collaborations to advance the clinical development and potential commercialization of Gedeptin-based combination therapies. For more information, visit www.geovax.com.
